ScholarIQanswers from OpenAlex

The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts

PaperCitations, authors & open-access status

The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts is a paper indexed in ScholarIQ from OpenAlex.

How many citations does The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts have?

ScholarIQcitation count

The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts has 51 citations in the OpenAlex counts ScholarIQ stores.

When was The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts published?

ScholarIQyear

The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts has 2010 year in the ScholarIQ index.

What is the open-access status of The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts?

ScholarIQoa status

The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts has hybrid oa status in the ScholarIQ index.

What is the DOI of The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts?

ScholarIQdoi

The DOI for The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts is on the source record.

What is the PMID of The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts?

ScholarIQpmid

The PMID for The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts is on the source record.

What is the OpenAlex record for The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts?

ScholarIQopenalex

The OpenAlex for The First Type III Repeat in Fibronectin Activates an Inflammatory Pathway in Dermal Fibroblasts is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial